Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders

Purpose: Stress-related disorders are among the most prevalent and expensive medical consequences of participation in military operations. Omega-3 fatty acids EPA/DHA derived from fish oil are known to benefit both neuronal development in the young, and cognition and mood in various populations.

It is possible that soldiers receiving Omega-3 EPA/DHA will exhibit significantly higher cognitive performance, better affect/mood state, and less combat stress symptomatology compared to the placebo after 12 weeks of supplementation. A goal would be to reduce the prevalence of combat stress injuries in military personnel.

This study is enrolling participants by invitation only.

Sponsor: DoD

Collaborator: GlaxoSmithKline

ClinicalTrials.gov Identifier: NCT01216982

Behavioral Activation for Post Traumatic Stress Disorder (PTSD)/ Depression Treatment in Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans

Purpose: The present study is a randomized, controlled trial that compares behavioral activation to usual VA care as early psychotherapeutic interventions for OIF/OEF veterans with post traumatic stress disorder, or PTSD and major depressive disorder (PTSD/MDD).

Sponsor: VA

ClinicalTrials.gov Identifier: NCT00805532

Telemedicine for Improved Delivery of Psychosocial Treatments for Post Traumatic Stress Disorder

Purpose: The objective of the proposed study is to conduct a systematic comparison of post traumatic stress disorder outcomes for veterans receiving exposure therapy via telemedicine versus in-person care. The primary aim is to determine feasibility: whether telemedicine can be used as a tool to extend effective, specialized mental health services, such as Prolonged Exposure therapy (PE; a therapy designed to help clients face fears related to a traumatic event), to veterans with limited access to care. A secondary aim is to determine if therapy delivered by telemedicine affects the quality of care in terms of clinical outcomes and the quality of patient-therapist interaction. A tertiary aim is to examine whether results from neuropsychological testing predict treatment outcomes.

Sponsor: Veterans Medical Research Foundation

Collaborators: DoD, University of Pennsylvania

ClinicalTrials.gov Identifier: NCT01158001

Clinical Trial of Fluoxetine in Anxiety and Depression in Children, and Associated Brain Changes

Purpose: This study uses functional magnetic resonance imaging to learn how the brain functions in adolescents receiving fluoxetine (Prozac®) cognitive behavioral therapy or interpersonal therapy for anxiety or depression in children/adolescents.

Sponsor: NIMH

ClinicalTrials.gov Identifier: NCT00018057

back to March articles